NPPA caps trade margins at 30 per cent for 137 anti-cancer medicines
Industry associations like IPA and OPPI welcomes the move; but highlight the need to ensure affordability and uninterrupted…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sudarshan Jain
How does India Pharma Inc stay relevant in Global Pharma’s new world order?
In Express Pharma's inaugural episode of Pharma Frontlines, Viveka Roychowdhury, Editor, Express Pharma, gets Sudarshan Jain IPA…
IPA hosts 11th edition of Global Pharmaceutical Quality Summit
Reportedly, 400+ delegates and 50 speakers were part of the summit
A biosimilar boost amid trade barriers
Even as India’s biggest pharma companies pursue biosimilars, product recalls related to manufacturing defects threaten to queer…
Industry experts respond to FDA move to streamline biosimilar development
The agency through a separate initiative also plans to make it easier for biosimilars to be developed as interchangeable with…
India invites proposals under PRIP scheme to propel Pharma‑MedTech R&D projects
Programme offers funding support from idea to market across early and later stage projects, with enhanced incentives for strategic…
Session 14 of FOPE & PharmaState Academy’s PULSE Program explores investigations & CAPA…
The session attracted over 250 attendees, reinforcing the PULSE series' role as a key learning platform for industry professionals
US tariffs leave Indian pharma unaffected, industry voices relief
Trump’s new tariffs impose 26% duty on India, while pharma remains exempt. Industry experts weigh in on the impact
Panel Discussion: The patient of the future: Shaping pharma’s next big opportunity
The Pharma Leadership and Innovation Conclave 2025 hosted a thought-provoking panel discussion on ‘The Patient of the Future:…
Balancing MAGA and MIGA
While the PILLS Act, aims for “strategically incentivising reshoring of essential medicines” to the US, India Pharma Inc cannot do…